A Common &quot;Scents&quot; Reminder to Take the Pill

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.

October 25th 2023

Treatment by Female Physicians Linked to Lower Mortality, Hospital Readmissions

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.

August 30th 2023

Study: COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Vedolizumab (Entyvio) SC Approved for Maintenance Therapy in Adults with Moderately to Severely Active Crohn Disease

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.

New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

Related Content

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.

October 25th 2023

Treatment by Female Physicians Linked to Lower Mortality, Hospital Readmissions

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.

August 30th 2023

Study: COVID-19 Booster Shots Elicit Longer Immunity than Primary Series Alone

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Vedolizumab (Entyvio) SC Approved for Maintenance Therapy in Adults with Moderately to Severely Active Crohn Disease

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.